Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
March 21, 2024 – Biotechnology, Pharmaceutical – Cancer Focus Fund, Eisbach Bio, funding, oncology, solid tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers
21 March 2024 — Martinsried, Germany and Texas, US — Eisbach Bio, a clinical-stage biotechnology company pioneering a new class of cancer medicines leveraging synthetic lethality to target specific proteins that are essential for the survival of cancer cells, and Cancer Focus Fund, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, US, to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $4.5m to support a phase 1/2 clinical trial of Eisbach’s lead candidate, EIS-12656, which will be conducted at MD Anderson.
EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors. PARP enzymes are involved in critical DNA repair processes. By hindering DNA repair, PARP inhibitors cause tumour cell death, and they have been effective therapies for many ovarian, breast, prostate and pancreatic cancers. However, their use has been limited by serious toxicities and the development of resistance. EIS-12656 inhibits the chromatin remodelling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation. EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process. In preclinical studies EIS-12656 overcame PARP inhibitor resistance and demonstrated a benign toxicity profile and blood-brain-barrier penetrance, as well as synergy with PARP inhibitors and other standard-of-care therapies.
“Overcoming the widespread resistance and debilitating side-effects of PARP inhibitors required us to re-think how we tackle the genetic vulnerabilities prevalent in these tumors,” said Dr Adrian Schomburg, founder and CEO of Eisbach. “EIS-12656 is a first-in-class small molecule that targets and shuts down the molecular process that reorganises the tumour genome upon DNA damage and PARP activation – a process that is essential to the survival of cancer cells. Based on its exceptional safety profile and promising activity in preclinical studies, we believe that EIS-12656 has the potential to benefit the many patients with tumours refractory to PARP inhibitors – patients who have few treatment options available today.”
Dr Andreas Ladurner, founder and CSO of Eisbach, and professor and chair of Physiological Chemistry at Ludwig-Maximilians-University of Munich, commented, “Most cancers contain genome reorganisation mechanisms that play critical and very specific roles in tumour biology. By identifying how each of these vital mechanisms is selectively regulated, we can exploit unique molecular vulnerabilities. This approach holds great promise for the discovery of new cancer drugs that are both selective and safe.”
“Eisbach’s distinctive and scientifically sophisticated approach to addressing common difficult-to-treat cancers aligns perfectly with our goals at Cancer Focus Fund,” said Ross Barrett, a founder and managing partner of Cancer Focus Fund. “We aim to help innovative young companies like Eisbach to rapidly advance unusually promising new cancer drugs into clinical trials with the help of the expert researchers and clinicians at MD Anderson. EIS-12656 has demonstrated the potential to treat many relapsed and refractory tumours more effectively and with fewer side effects than current therapies, and we look forward to following the progress of this exciting first-in-class compound as it proceeds in clinical development. We also are delighted to expand our geographic reach with this first investment in a biotech company based in Germany, with its rich history of biomedical innovation.”
Timothy A Yap MBBS PhD, professor of Investigational Cancer Therapeutics, and vice president and head of Clinical Development in the Therapeutics Discovery division at MD Anderson, will serve as principal investigator of the trial.
About Eisbach
Eisbach is a pioneering, clinical-stage biotech company focused on precision oncology, aiming to disrupt tumour growth by targeting genetic vulnerabilities. The company develops allosteric drugs that selectively disrupt molecular mechanisms, also known as molecular machines, which are vital for tumour genome reorganisation. Eisbach combines the genetic vulnerabilities present in defined tumours (synthetic lethality) with its proprietary drug discovery platform, ALLOS, which targets the unique molecular vulnerability of its drug targets, to create first-in-class therapies with fewer side effects. The company’s pipeline includes several small molecule candidates targeting chromatin reorganisation that enable potent combination therapies and suppress resistance mechanisms in cancer treatment. For more information, visit www.eisbach.bio.
About Cancer Focus Fund
The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center, US. The fund provides investment support to advance promising cancer therapies that are close to being tested in humans or are in early clinical development, as well as the clinical trial expertise and infrastructure of MD Anderson and strategic partners Ochsner Health System Precision Cancer Therapies Program New Orleans and the LSU Feist Weiller Cancer Center Shreveport. The Fund’s objective is to leverage this unique combination to provide investors with superior risk-adjusted returns. In collaboration with partner MD Anderson, the Cancer Focus Fund provides both capital and translational research expertise with the goal of accelerating the development of novel cancer therapies that result in better outcomes for patients while generating returns for investors. Visit: cancerfocusfund.com.
